FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281385503> ?p ?o ?g. }

• W4281385503 endingPage "1826" @default.
• W4281385503 startingPage "1816" @default.
• W4281385503 abstract "This study aimed to evaluate the effect of dapagliflozin on 1 and 3-month maximal functional capacity in patients with stable heart failure with reduced ejection fraction (HFrEF).In this multicentre, randomized, double-blind clinical trial, 90 stable patients with HFrEF were randomly assigned to receive either dapagliflozin (n = 45) or placebo (n = 45). The primary outcome was a change in peak oxygen consumption (peakVO2 ) at 1 and 3 months. Secondary endpoints were changes at 1 and 3 months in 6-min walk test (6MWT) distance, quality of life (Minnesota Living with Heart Failure Questionnaire [MLHFQ]), and echocardiographic parameters (diastolic function, left chamber volumes, and left ventricular ejection fraction). We used linear mixed regression analysis to compare endpoint changes. Estimates were adjusted for multiple comparisons. The mean age was 67.1 ± 10.7 years, 69 (76.7%) were men, 29 (32.2%) had type 2 diabetes, and 80 (88.9%) were in New York Heart Association class II. Baseline means of peakVO2 , 6MWT and MLHFQ were 13.2 ± 3.5 ml/kg/min, 363 ± 110 m, and 23.1 ± 16.2, respectively. The median (25th-75th percentile) of N-terminal pro-brain natriuretic peptide was 1221 pg/ml (889-2100). Most patients were on treatment with sacubitril/valsartan (88.9%), beta-blockers (91.1%), and mineralocorticoid receptor antagonists (74.4%). PeakVO2 significantly increased in patients on treatment with dapagliflozin (1 month: +Δ 1.09 ml/kg/min, 95% confidence interval [CI] 0.14-2.04; p = 0.021, and 3 months: +Δ 1.06 ml/kg/min, 95% CI 0.07-2.04; p = 0.032). Similar positive findings were found when evaluating changes from baseline. No significant differences were observed in secondary endpoints.Among patients with stable HFrEF, dapagliflozin resulted in a significant improvement in peakVO2 at 1 and 3 months.ClinicalTrials.gov Identifier: NCT04197635." @default.
• W4281385503 created "2022-05-25" @default.
• W4281385503 creator A5000935304 @default.
• W4281385503 creator A5001418113 @default.
• W4281385503 creator A5001684129 @default.
• W4281385503 creator A5003061525 @default.
• W4281385503 creator A5003648008 @default.
• W4281385503 creator A5005400780 @default.
• W4281385503 creator A5005708664 @default.
• W4281385503 creator A5008591831 @default.
• W4281385503 creator A5009739665 @default.
• W4281385503 creator A5016434779 @default.
• W4281385503 creator A5019360089 @default.
• W4281385503 creator A5019408483 @default.
• W4281385503 creator A5020245169 @default.
• W4281385503 creator A5034486091 @default.
• W4281385503 creator A5039483633 @default.
• W4281385503 creator A5040773765 @default.
• W4281385503 creator A5043612885 @default.
• W4281385503 creator A5046692355 @default.
• W4281385503 creator A5047182336 @default.
• W4281385503 creator A5049512884 @default.
• W4281385503 creator A5050982770 @default.
• W4281385503 creator A5051684730 @default.
• W4281385503 creator A5053528763 @default.
• W4281385503 creator A5059676686 @default.
• W4281385503 creator A5066737871 @default.
• W4281385503 creator A5067397221 @default.
• W4281385503 creator A5068631015 @default.
• W4281385503 creator A5068633077 @default.
• W4281385503 creator A5069433292 @default.
• W4281385503 creator A5087461526 @default.
• W4281385503 creator A5090224812 @default.
• W4281385503 date "2022-06-06" @default.
• W4281385503 modified "2023-10-11" @default.
• W4281385503 title "Short‐term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (<scp>DAPA‐VO₂</scp>): a randomized clinical trial" @default.
• W4281385503 cites W2755146915 @default.
• W4281385503 cites W2772204795 @default.
• W4281385503 cites W2787201390 @default.
• W4281385503 cites W2794419513 @default.
• W4281385503 cites W2801099842 @default.
• W4281385503 cites W2917132355 @default.
• W4281385503 cites W2974260792 @default.
• W4281385503 cites W2982075999 @default.
• W4281385503 cites W3000647500 @default.
• W4281385503 cites W3023653525 @default.
• W4281385503 cites W3025899746 @default.
• W4281385503 cites W3100542962 @default.
• W4281385503 cites W3102766101 @default.
• W4281385503 cites W3133124837 @default.
• W4281385503 cites W3173243170 @default.
• W4281385503 cites W3203052839 @default.
• W4281385503 cites W4210520398 @default.
• W4281385503 cites W4214940159 @default.
• W4281385503 doi "https://doi.org/10.1002/ejhf.2560" @default.
• W4281385503 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35604416" @default.
• W4281385503 hasPublicationYear "2022" @default.
• W4281385503 type Work @default.
• W4281385503 citedByCount "15" @default.
• W4281385503 countsByYear W42813855032022 @default.
• W4281385503 countsByYear W42813855032023 @default.
• W4281385503 crossrefType "journal-article" @default.
• W4281385503 hasAuthorship W4281385503A5000935304 @default.
• W4281385503 hasAuthorship W4281385503A5001418113 @default.
• W4281385503 hasAuthorship W4281385503A5001684129 @default.
• W4281385503 hasAuthorship W4281385503A5003061525 @default.
• W4281385503 hasAuthorship W4281385503A5003648008 @default.
• W4281385503 hasAuthorship W4281385503A5005400780 @default.
• W4281385503 hasAuthorship W4281385503A5005708664 @default.
• W4281385503 hasAuthorship W4281385503A5008591831 @default.
• W4281385503 hasAuthorship W4281385503A5009739665 @default.
• W4281385503 hasAuthorship W4281385503A5016434779 @default.
• W4281385503 hasAuthorship W4281385503A5019360089 @default.
• W4281385503 hasAuthorship W4281385503A5019408483 @default.
• W4281385503 hasAuthorship W4281385503A5020245169 @default.
• W4281385503 hasAuthorship W4281385503A5034486091 @default.
• W4281385503 hasAuthorship W4281385503A5039483633 @default.
• W4281385503 hasAuthorship W4281385503A5040773765 @default.
• W4281385503 hasAuthorship W4281385503A5043612885 @default.
• W4281385503 hasAuthorship W4281385503A5046692355 @default.
• W4281385503 hasAuthorship W4281385503A5047182336 @default.
• W4281385503 hasAuthorship W4281385503A5049512884 @default.
• W4281385503 hasAuthorship W4281385503A5050982770 @default.
• W4281385503 hasAuthorship W4281385503A5051684730 @default.
• W4281385503 hasAuthorship W4281385503A5053528763 @default.
• W4281385503 hasAuthorship W4281385503A5059676686 @default.
• W4281385503 hasAuthorship W4281385503A5066737871 @default.
• W4281385503 hasAuthorship W4281385503A5067397221 @default.
• W4281385503 hasAuthorship W4281385503A5068631015 @default.
• W4281385503 hasAuthorship W4281385503A5068633077 @default.
• W4281385503 hasAuthorship W4281385503A5069433292 @default.
• W4281385503 hasAuthorship W4281385503A5087461526 @default.
• W4281385503 hasAuthorship W4281385503A5090224812 @default.
• W4281385503 hasConcept C126322002 @default.
• W4281385503 hasConcept C134018914 @default.
• W4281385503 hasConcept C142724271 @default.
• W4281385503 hasConcept C164705383 @default.
• W4281385503 hasConcept C168563851 @default.

• next